Nephrology research hub

A Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects with IgA Nephropathy on Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i) (The ASSIST study)

This study looks at a new medicine called atrasentan for people with a kidney condition called IgA nephropathy. It compares atrasentan with a dummy pill (placebo) to see if it helps reduce protein in the urine, even if participants are already taking another kidney medicine called an SGLT2 inhibitor.